203 related articles for article (PubMed ID: 16273044)
1. Pessimistic response to FDA leadership change.
Kling J
Nat Biotechnol; 2005 Nov; 23(11):1325. PubMed ID: 16273044
[No Abstract] [Full Text] [Related]
2. An impossible job.
Nat Biotechnol; 2005 Nov; 23(11):1321. PubMed ID: 16273042
[No Abstract] [Full Text] [Related]
3. The big gap at the FDA.
Stipp D
Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
[No Abstract] [Full Text] [Related]
4. Mission: promoting, protecting the public health. FDA Commissioner Mark B. McClellan. Interview by Ray Formanek Jr.
McClellan MB
FDA Consum; 2003; 37(2):12-7. PubMed ID: 12715764
[No Abstract] [Full Text] [Related]
5. FDA embraces risk-management approach.
Fox JL
Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
[No Abstract] [Full Text] [Related]
6. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
7. Sandoz sues FDA over delay in first biogeneric approval.
Fox JL
Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
[No Abstract] [Full Text] [Related]
8. FDA begins product approval initiative.
Lewis C
FDA Consum; 2003; 37(3):10-1. PubMed ID: 12793386
[No Abstract] [Full Text] [Related]
9. New FDA Commissioner sees challenges, opportunities.
Lewis C
FDA Consum; 2003; 37(1):9. PubMed ID: 12625298
[No Abstract] [Full Text] [Related]
10. The FDA: a dromedary tale.
Nat Biotechnol; 1997 Jan; 15(1):1. PubMed ID: 9035089
[No Abstract] [Full Text] [Related]
11. FDA appointee faces angry, demoralized staff.
Fox JL
Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
[No Abstract] [Full Text] [Related]
12. Vision and will: the future of the FDA.
Epstein D
Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098
[No Abstract] [Full Text] [Related]
13. A turbulent year at the agency.
Ratner M
Nat Biotechnol; 2006 Feb; 24(2):145-51. PubMed ID: 16465153
[No Abstract] [Full Text] [Related]
14. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
15. Off-label promotion.
Somberg J
Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
[No Abstract] [Full Text] [Related]
16. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
17. 2006 drug approvals: finding the niche.
Owens J
Nat Rev Drug Discov; 2007 Feb; 6(2):99-101. PubMed ID: 17342860
[No Abstract] [Full Text] [Related]
18. FDA scrutinizes human stem cell therapies.
Fox JL
Nat Biotechnol; 2008 Jun; 26(6):598-9. PubMed ID: 18536668
[No Abstract] [Full Text] [Related]
19. Regulatory watch: FDA PDUFA goals missed.
Hay M
Nat Rev Drug Discov; 2009 Jan; 8(1):10. PubMed ID: 19116619
[No Abstract] [Full Text] [Related]
20. IL-1 trap go-ahead.
Ratner M
Nat Biotechnol; 2008 May; 26(5):485. PubMed ID: 18464767
[No Abstract] [Full Text] [Related]
[Next] [New Search]
